1.原文連結(必須檢附)：
http://ppt.cc/T68W
2.原文內容：
Second-Line nal-IRI (MM-398) Shows Consistent Improvement in Clinical
Outcomes in Metastatic Pancreatic Cancer
JAN 16, 2015
A deeper dive of data from NAPOLI-1, a randomized, controlled, open-label
phase III trial conducted in patients with gemcitabine-refractory metastatic
pancreatic cancer, bolsters support for use of MM-398 plus 5-fluorouracil
(5-FU)/leucovorin over 5-FU/leucovorin in the second-line setting (Abstract
234). Patients who received at least 80% of planned treatment during the
first 6 weeks of the study achieved a 3.8-month improvement in survival when
MM-398 was added to the chemotherapy backbone, according to data presented by
Li-Tzong Chen, MD, PhD, of the National Institute of Cancer Research and the
National Health Research Institutes in Taiwan.
3.心得/評論(必需填寫)：
原文未完 請連接網址